Closed venture fund worth $1.3 billion by Frazier Life Sciences
Frazier Life Sciences, a venture capital firm based in the United States, has been making significant strides in the biotech industry since 2020. The firm's primary focus has been on investing in innovative therapeutics, particularly in the fields of genetic medicine, autoimmune diseases, and ophthalmology.
One of Frazier's key investments is Lexeo Therapeutics, a company developing treatments for genetic cardiovascular diseases. Frazier co-led a financing round in 2020, providing Lexeo with funding through 2028 for its cardiovascular genetic medicine pipeline. The company is currently working on treatments for Friedreich ataxia cardiomyopathy (LX2006) and PKP2-related arrhythmogenic cardiomyopathy. Interim clinical data for these treatments have shown strong increases in target protein expression and reductions in cardiac disease markers, with a registrational study planned by early 2026.
Another significant investment is Hillstar Bio, a company developing precision therapies for autoimmune diseases. Frazier was a key investor in a $67 million Series A round in March 2025. Hillstar's aim is to selectively deplete harmful T cells while preserving healthy ones, with clinical trials planned for the near future.
Frazier has also invested in Augustine Therapeutics and related ventures, such as Callio. These companies are focused on antibody-drug conjugate therapeutics and other biotech innovations.
The therapeutic focus of Frazier Life Sciences extends beyond these areas, encompassing genetic medicines, immune modulation, and targeted therapies for chronic and rare diseases. The firm places a strong emphasis on precision, cell-selective treatment mechanisms, and conditions such as genetic cardiomyopathies, autoimmune diseases, and ophthalmic conditions.
Since 2016, Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds. Notable investments include Mirum Pharmaceuticals, NewAmsterdam Pharma, Tarsus Pharmaceuticals, Amunix Pharmaceuticals (acquired by Sanofi), and Alpine Immune Sciences (later acquired by Vertex).
Frazier Life Sciences operates with a hands-on, collaborative approach. The firm's team includes seven investment partners and over 35 investment professionals, operating professionals, and senior advisors. The fund has received strong support from both longstanding and new limited partners.
In 2021, Frazier Life Sciences also raised more than $1.7 billion in long-only public funds. The firm has closed Frazier Life Sciences XII, L.P. (FLS XII) with over $1.3 billion in capital commitments. FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies.
The potential therapeutic programs Frazier Life Sciences is working on have the potential to address significant medical needs. Since 2020, Frazier Life Sciences has led to the creation of 25 new companies. The firm looks forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs and transform the biotech industry.
In summary, Frazier Life Sciences has demonstrated a clear commitment to transformative, precision medicine approaches. The firm's investments in early to mid-stage biotech companies developing next-generation therapeutics in genetic cardiovascular diseases, autoimmune disorders, and targeted biologics are set to make a significant impact in the medical field.
- Frazier Life Sciences, with its investments in companies like Lexeo Therapeutics for genetic cardiovascular diseases and Hillstar Bio for autoimmune diseases, is actively contributing to the medical-conditions sector, particularly in the realm of health-and-wellness.
- In addition to its biotech investments, Frazier Life Sciences has also delved into the finance and investing domain by providing funding to promising ventures, such as Hillstar Bio, which secured $67 million in Series A round, demonstrating its involvement in the broader financial landscape.
